- Home
- FMAO vs CERS Comparison
FMAO vs CERS Comparison
Compare FMAO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- CERS
- Stock Information
- Founded
- FMAO 1897
- CERS 1991
- Country
- FMAO United States
- CERS United States
- Employees
- FMAO N/A
- CERS N/A
- Industry
- FMAO Savings Institutions
- CERS EDP Services
- Sector
- FMAO Finance
- CERS Technology
- Exchange
- FMAO Nasdaq
- CERS Nasdaq
- Market Cap
- FMAO 377.5M
- CERS 324.3M
- IPO Year
- FMAO N/A
- CERS 1997
- Fundamental
- Price
- FMAO $30.81
- CERS $1.79
- Analyst Decision
- FMAO Hold
- CERS Buy
- Analyst Count
- FMAO 2
- CERS 3
- Target Price
- FMAO $26.00
- CERS $3.17
- AVG Volume (30 Days)
- FMAO 23.7K
- CERS 2.2M
- Earning Date
- FMAO 10-30-2024
- CERS 10-30-2024
- Dividend Yield
- FMAO 2.81%
- CERS N/A
- EPS Growth
- FMAO N/A
- CERS N/A
- EPS
- FMAO 1.68
- CERS N/A
- Revenue
- FMAO $98,003,000.00
- CERS $176,229,000.00
- Revenue This Year
- FMAO N/A
- CERS $23.85
- Revenue Next Year
- FMAO $7.11
- CERS $10.89
- P/E Ratio
- FMAO $19.14
- CERS N/A
- Revenue Growth
- FMAO N/A
- CERS 14.71
- 52 Week Low
- FMAO $17.29
- CERS $1.38
- 52 Week High
- FMAO $32.84
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- FMAO 66.79
- CERS 55.52
- Support Level
- FMAO $27.05
- CERS $1.59
- Resistance Level
- FMAO $32.84
- CERS $1.83
- Average True Range (ATR)
- FMAO 0.95
- CERS 0.12
- MACD
- FMAO 0.40
- CERS 0.02
- Stochastic Oscillator
- FMAO 68.62
- CERS 93.55
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.